48,470
edits
Difference between revisions of "Neuroendocrine neoplasms"
Jump to navigation
Jump to search
Neuroendocrine neoplasms (view source)
Revision as of 19:55, 5 December 2023
, 19:55, 5 December 2023no edit summary
| (One intermediate revision by the same user not shown) | |||
| Line 60: | Line 60: | ||
*[[CDX2]] -ve/+ve. | *[[CDX2]] -ve/+ve. | ||
**+ve suggests ileum, appendix or colon origin.<ref name=pmid22180832>{{Cite journal | last1 = Saad | first1 = RS. | last2 = Ghorab | first2 = Z. | last3 = Khalifa | first3 = MA. | last4 = Xu | first4 = M. | title = CDX2 as a marker for intestinal differentiation: Its utility and limitations. | journal = World J Gastrointest Surg | volume = 3 | issue = 11 | pages = 159-66 | month = Nov | year = 2011 | doi = 10.4240/wjgs.v3.i11.159 | PMID = 22180832 }}</ref> | **+ve suggests ileum, appendix or colon origin.<ref name=pmid22180832>{{Cite journal | last1 = Saad | first1 = RS. | last2 = Ghorab | first2 = Z. | last3 = Khalifa | first3 = MA. | last4 = Xu | first4 = M. | title = CDX2 as a marker for intestinal differentiation: Its utility and limitations. | journal = World J Gastrointest Surg | volume = 3 | issue = 11 | pages = 159-66 | month = Nov | year = 2011 | doi = 10.4240/wjgs.v3.i11.159 | PMID = 22180832 }}</ref> | ||
*Serotonin -ve/+ve. | |||
**+ve suggests jejuno-ileal origin.{{fact}} | |||
Hormone products: | Hormone products: | ||
| Line 107: | Line 109: | ||
*[[Basics]]. | *[[Basics]]. | ||
*[[Goblet cell carcinoid]]. | *[[Goblet cell carcinoid]]. | ||
*[[Mixed neuroendocrine-nonneuroendocrine neoplasm]] (MiNEN). | |||
=References= | =References= | ||